View Older Stories View More Recent Stories

Jul 5, 2023 07:05AM Ionis to present at upcoming investor conference
Jun 30, 2023 04:09PM Biogen (BIIB) Presents New Data on SPINRAZA
Jun 30, 2023 04:08PM New data highlight potential benefit of SPINRAZA® (nusinersen) in infants and toddlers with unmet medical needs after gene therapy
Jun 30, 2023 04:06PM New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
Jun 1, 2023 07:10AM Ionis Pharmaceuticals (IONS) announces positive donidalorsen late-stage clinical progress in HAE
Jun 1, 2023 07:05AM Ionis announces positive donidalorsen late-stage clinical progress in HAE
May 10, 2023 07:05AM Ionis to host 2023 virtual Annual Meeting of Stockholders
May 9, 2023 07:05AM Ionis to present at upcoming investor conferences
Apr 26, 2023 05:41AM Ionis Pharmaceuticals (IONS) Announces FDA Approval of QALSODY
Apr 25, 2023 07:10PM FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS
Apr 24, 2023 07:01AM Ionis Pharmaceuticals (IONS) says Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
Apr 24, 2023 07:00AM Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
Apr 20, 2023 07:05AM Ionis to hold first quarter 2023 financial results webcast
Mar 29, 2023 08:45AM New data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease
Mar 28, 2023 07:05AM Ionis to present at upcoming investor conferences
Mar 27, 2023 05:49AM Ionis Pharmaceuticals (IONS) Reports Positive 66-week Phase 3 Data for eplontersen
Mar 27, 2023 02:00AM Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN
Mar 23, 2023 05:31AM Ionis Pharmaceuticals (IONS) Reports FDA's AdCom Voted Unanimously for Accelerated Approval of tofersen
Mar 22, 2023 11:01PM Ionis accounces FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS
Mar 7, 2023 07:06AM Ionis Pharmaceuticals (IONS) announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy
Mar 7, 2023 07:05AM Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
Feb 28, 2023 07:05AM Ionis to present at upcoming investor conferences
Feb 22, 2023 07:01AM Ionis reports fourth quarter and full year 2022 financial results
Feb 21, 2023 07:06AM Ionis Pharmaceuticals (IONS) to Present New donidalorsen Data
Feb 21, 2023 07:05AM Ionis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
Feb 8, 2023 07:05AM Ionis to hold fourth quarter and full year 2022 financial results webcast
Feb 1, 2023 09:06AM Ionis Pharmaceuticals (IONS) Announces GSK Initiates Two Phase 3 Trials for bepirovirsen
Feb 1, 2023 09:05AM Ionis announces GSK has advanced bepirovirsen into Phase 3 development
Jan 31, 2023 07:07AM Ionis Pharmaceuticals (IONS) Granted FDA Fast Track Designation for olezarsen
Jan 31, 2023 07:05AM Ionis receives FDA Fast Track designation for olezarsen in patients with familial chylomicronemia syndrome
Jan 26, 2023 09:30AM Ionis Chief Scientific Officer C. Frank Bennett, Ph.D. to receive Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research
Jan 9, 2023 09:15AM Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
Jan 9, 2023 09:15AM Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
Jan 9, 2023 09:06AM Ionis Pharmaceuticals (IONS), Royalty Pharma (RPRX) enter into royalty agreement for up to $1.1 billion
Jan 9, 2023 09:05AM Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness
Jan 4, 2023 07:30AM Biogen (BIIB), Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
Jan 4, 2023 07:30AM Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
Jan 4, 2023 07:30AM Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
Jan 4, 2023 07:05AM Ionis to present at 41st Annual J.P. Morgan Healthcare conference
Dec 5, 2022 07:34AM Ionis Pharmaceuticals (IONS) announces EMA accepts Marketing Authorization Application of tofersen to treat rare, genetic form of ALS
Dec 5, 2022 07:30AM Ionis announces European Medicines Agency accepts Marketing Authorization Application of tofersen to treat rare, genetic form of ALS
Nov 14, 2022 06:05AM Ionis Pharmaceuticals (IONS) Partners with Metagenomi to Add Gene Editing
Nov 14, 2022 06:05AM Ionis partners with Metagenomi to add gene editing to its broad technology platform
Nov 14, 2022 05:47AM Ionis (IONS) Reports Positive Phase 2 Data from Open Label Extension Study of donidalorsen
Nov 13, 2022 01:01PM Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting
Nov 10, 2022 07:05AM Ionis to present at upcoming investor conferences
Nov 9, 2022 07:00AM Ionis reports third quarter financial results
Nov 8, 2022 10:59AM Ionis Pharmaceuticals (IONS) Reports Positive Data from GSK's Phase 2b Study of bepirovirsen
Nov 8, 2022 10:57AM Ionis announces positive data from GSK's Phase 2b clinical study of bepirovirsen
Nov 7, 2022 07:05AM Ionis Pharmaceuticals (IONS) Reports Positive Phase 2 data in Patients with IgA Nephropathy
View More Recent Stories View Older Stories